Industrial Biotechnology Innovation Catalyst

What Industrial Biotechnology Innovation Catalyst does

The Industrial Biotechnology Innovation Catalyst (IBIC) is a north-west England consortium hosted by the Manchester Institute of Biotechnology (MIB) at the University of Manchester, coordinating the regional industrial biotechnology pipeline from laboratory research to commercial deployment. IBIC connects higher education institutions, businesses, talent development programmes, policy stakeholders, and funding bodies to translate bio-based discoveries into market applications across pharmaceuticals, chemicals, materials, environmental sustainability, and diagnostics. The consortium is anchored by MIB, which houses over 40 research groups, 250+ PhD students, and 80+ MSc students working across biology, chemistry, engineering, and computational sciences.

IBIC's technology stack is delivered through MIB's research facilities, including the BioAutomation Facility, the Manchester Protein Structure Facility, the Biomolecular NMR Facility, the Michael Barber Centre for Collaborative Mass Spectrometry (26 MS platforms), the Biomolecular Simulation and Chemical Modelling Facility, and the UK DNP MAS NMR Facility. Dedicated programmes include the International Centre for Enzyme Design (ICED) for deep learning protein design, the BioProcess IDLA industrial doctoral training partnership with the Universities of Bristol and York, the Future Biomanufacturing Research Hub (FBRH), the Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop), the Sustainable Engineering Plastics (SEP) Hub, and the Manchester Biomolecule Engineering Centre (MBEC) for national training. IBIC runs a competitive funding call programme (next round closing 10 September 2026), knowledge exchange events, webinars, and an annual conference.

IBIC does not operate as a commercial product business. Its revenue mechanics derive from public and charitable research grants (over £100m in live grant income from UKRI councils including BBSRC and EPSRC, ARIA, Wellcome Trust, Gates Foundation, and Royal Society), industry collaboration contracts (AstraZeneca, Equinor, Siemens, Polestar, Biffa, Vita), technology licensing, and spin-out company creation. Notable spin-outs include Manchester BIOGEL (acquired by Cell Guidance Systems in 2023), C3 BIOTECH, C4X Discovery, Imperagen, Holiferm, and Dekiln. IBIC also offers funded doctoral training programmes through BBSRC NWDTP, BioProcess IDLA, IBioIC CTP, BIOAID, CODE-M, and A*STAR, alongside a free Industrial Biotechnology MOOC on Coursera that has reached over 10,000 learners. Quantified outputs include over 1,000 enzymes commercialised across 20+ reaction types, a SNAr1.3 enzyme performing over 4,000 reaction cycles, and a proposed circular bioprocess potentially reducing waste management carbon footprint by up to 62%.

Name

Industrial Biotechnology Innovation Catalyst

Legal name

Industrial Biotechnology Innovation Catalyst

Website

https://mib.manchester.ac.uk

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

The Industrial Biotechnology Innovation Catalyst (IBIC) is a north-west England consortium hosted by the University of Manchester's MIB that connects academic research, industry partners, talent, and funders to translate bio-based discoveries into commercial applications across pharmaceuticals, chemicals, materials, and environmental sustainability.

Ownership category

akta.pro rank

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Grants and Public Funding: The consortium and its host institution (MIB) operate primarily on public and charitable research funding. IBIC is a funded consortium, and MIB carries over £100m in live grant income from UKRI councils (BBSRC, EPSRC), ARIA, Wellcome Trust, Gates Foundation, Royal Society, and other public/charitable sources. Funding supports collaborative research projects across academia and industry.
2. Industry Collaboration and Contract Research: MIB and its researchers engage in collaborative R&D projects with industrial partners including pharmaceutical, chemicals, materials, and energy companies. These arrangements typically involve co-funded research, technology development agreements, and access to facilities and expertise in exchange for industry contribution.
3. Technology Licensing and Spin-out Companies: MIB has a strong track record of translating research into commercial outcomes through spin-out companies. Notable spinouts include Manchester BIOGEL, C3 BIOTECH, C4X Discovery, Dekiln, Imperagen, and Holiferm. Licensing of proprietary technologies and know-how to industry partners generates commercial value.
4. Training and Education Programmes: IBIC and MIB offer funded doctoral training programmes (BBSRC NWDTP, BioProcess IDLA, IBioIC CTP, CODE-M, BIOAID, A*STAR), continuing professional development through MBEC, and the free Industrial Biotechnology MOOC on Coursera with over 10,000 learners. Some training programmes carry industry co-funding.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

IBIC is a north-west England consortium that connects higher education institutions, businesses, policymakers, funders and talent to turn bio-based research into real-world industrial biotechnology solutions. Its primary services are competitive funding calls for IB SMEs and academic collaborators, knowledge exchange events and an annual conference, a free Industrial Biotechnology MOOC on Coursera, and access to the Manchester Institute of Biotechnology's world-class facilities, research centres and doctoral training programmes. Underlying the consortium is MIB's research and technology base spanning enzyme engineering, synthetic biology, structural biology, AI/ML-driven protein design, and bioprocess scale-up.

Product overview

IBIC is a consortium model that bundles community access, expert matching, funding streams, knowledge exchange, and commercialisation support for industrial biotechnology. The broader MIB ecosystem includes world-class research facilities (BioAutomation, Biophysical Spectroscopy, Biomolecular NMR, Mass Spectrometry, Protein Structure), research centres (CADDA, COEBP, FBRH, ICED, MBEC, MBCCMS, NaCTeM), educational programmes (Industrial Biotechnology MOOC, doctoral training), and spinout companies (Manchester BIOGEL/PeptiGel, C3 Biotechnologies, C4X Discovery, Imperagen, Holiferm) spanning enzyme engineering, biocatalysis, sustainable manufacturing, and advanced therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• BioProcess IDLA: Industrial doctoral training in Biocatalysis and Protein Engineering for sustainable synthesis, in partnership with Universities of Manchester, Bristol and York
• CoEBio3
• Industrial Biotechnology Innovation Catalyst

Products and services

• Industrial Biotechnology Innovation Catalyst (IBIC) Consortium A consortium-based service that provides community access, expert matching, competitive funding calls, knowledge exchange events, an annual conference and commercialisation support for industrial biotechnology in the north-west of England.
• BioAutomation Facility

Quantifiable outcome

• Over 1,000 enzymes commercialised covering 20+ reaction types, significantly expanding biocatalytic options for manufacturing.
• +5 more outcomes

Named customers9 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

Partnerships

27 partnerships are on record, tiered core and secondary.

• AstraZenecacoreStrategic or Co-development Partner · 1 January 2026AstraZeneca is a named industry partner in the BioProcess IDLA doctoral training programme jointly led by the Universities of Manchester, Bristol and York. AstraZeneca also has a proprietary partnership with C4X Discovery using its Conformetrix NMR platform for drug molecule shape measurement. AstraZeneca has been identified as a partner company that has worked with MIB researchers on biocatalysis and drug manufacturing projects.
• University of BristolcoreStrategic or Co-development PartnerUniversity of Bristol is a joint lead of the BioProcess IDLA industrial doctoral training programme in biocatalysis and protein engineering for sustainable synthesis, alongside the Universities of Manchester and York.
• University of YorkcoreStrategic or Co-development PartnerUniversity of York is a joint lead of the BioProcess IDLA industrial doctoral training programme in biocatalysis and protein engineering for sustainable synthesis, alongside the Universities of Manchester and Bristol.
• EquinorsecondaryStrategic or Co-development PartnerEquinor ASA, a global energy company, is collaborating with University of Manchester researchers on a project to understand how microbes in deep underground CO2 storage sites could impact the success of carbon capture and storage (CCS), investigating microbial impact on geological carbon storage.
• IBioIC (Industrial Biotechnology Innovation Community)coreStrategic or Co-development PartnerIBioIC runs the Collaborative Training Partnership (CTP) funding four-year PhD studentships with the goal of providing industry-ready graduates for the biotechnology sector. IBioIC CTP is one of five doctoral training partnerships linked to MIB.
• Future Biomanufacturing Research Hub (FBRH)coreStrategic or Co-development PartnerFuture BRH (FBRH) is an EPSRC/BBSRC-funded biomanufacturing accelerator coordinating UK academic, HVM catapult and industrial capabilities to enable the complete biomanufacturing innovation pipeline. Nigel Scrutton is a founding director of C3 BIOTECH, which works with Future BRH on techno-economic analysis to commercialise its fuels portfolio.
• Future BRH / Future Biomanufacturing Research HubcoreStrategic or Co-development PartnerFBRH works with C3 BIOTECH on techno-economic analysis and environmental impact assessments for scaling laboratory processes into pilot and demonstrator programmes. The Hub coordinates biomanufacturing innovation pipeline across UK academia, HVM catapult and industry.
• Henry Royce InstitutesecondaryStrategic or Co-development PartnerHenry Royce Institute (the UK's national materials research institute) collaborates with MIB researchers on biomaterials and biomedical scaffold development. Mark Dunstan was appointed Royce Technology Platform Lead for Automated Engineering of Biology for Material Discovery.
• CryoLogyxsecondaryStrategic or Co-development PartnerCryoLogyx partnered with MIB researchers led by Professor Matthew Gibson to develop breakthrough cryopreservation technology (PaDT formulation) for 'blood on demand' emergency transfusion applications, published in Cryobiology journal.
• Queen’s University BelfastsecondaryStrategic or Co-development PartnerQueen's University Belfast co-runs the BIOAID (AI-Driven Industrial Biocatalysis) doctoral training programme with MIB, training scientists in AI and data-driven approaches for translational biocatalysis.
• A*STAR (Agency for Science, Technology and Research, Singapore)secondaryOthersA*STAR runs a four-year funded PhD programme enabling postgraduate researchers in science and engineering to spend two years at The University of Manchester and two years at an A*STAR research institute in Singapore.
• Sustainable Engineering Plastics (SEP) HubcoreStrategic or Co-development PartnerSEP Hub is an EPSRC-funded £13.6m initiative with University of Warwick and UCL, engaging over 60 industry partners (Siemens, Polestar, Biffa, Vita) to assess and improve sustainability of greener materials and remanufacturing processes. MIB's Professor Michael Shaver leads the Manchester team.
• Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop)coreStrategic or Co-development PartnerC-Loop Hub is a £14m EPSRC initiative led by University of Edinburgh with MIB as a key partner, exploring how engineered microbial systems can convert carbon-rich industrial waste into high-value products. Professor Neil Dixon leads the Manchester team. Over 40 industry collaborators. The UK's first BioFactory will be established.
• Heriot-Watt University (FlexBio scale-up facility)secondaryStrategic or Co-development PartnerHeriot-Watt University's FlexBio scale-up facility collaborated on the cyanobacteria citramalate production research published in Biotechnology for Biofuels and Bioproducts, supporting scale-up of the 2-litre to 5-litre reactor process.
• Pankhurst InstitutesecondaryStrategic or Co-development PartnerProfessor Sophia Ananiadou serves as Deputy Director of the Pankhurst Institute, which focuses on health technology innovation involving AI and advanced engineering. MIB researchers collaborate with the Pankhurst Institute on health-related biotechnology research.
• John Innes CentresecondaryStrategic or Co-development PartnerJohn Innes Centre is a partner in the synPAC (synthetic plant chromosome) project, contributing highly efficient methods for direct transfer of synthetic chromosomes to crop plants.
• Earlham InstitutesecondaryStrategic or Co-development PartnerEarlham Institute leads three areas of the synPAC project: potato tissue atlas and regulatory element discovery, assembly and testing of a potato regulatory element library through the Earlham Biofoundry, and engineering synPAC components.
• Sci-Tech DaresburysecondaryStrategic or Co-development PartnerSci-Tech Daresbury is a science and technology campus featured in IBIC's September 2026 webinar on Science and Innovation Campuses. Science Parks and Campuses are described as important hubs for early-stage and scaling science and technology companies providing laboratory and related infrastructure.
• STFC (Science and Technology Facility Council)secondaryStrategic or Co-development PartnerSTFC (Science and Technology Facility Council) is represented by Amy Farrington at IBIC's September 2026 webinar on Science and Innovation Campuses, providing expertise on technology facilities and support for scaling science companies.
• University of EdinburghcoreStrategic or Co-development PartnerUniversity of Edinburgh leads the Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop, £14m) of which MIB is a key partner. The collaboration addresses how engineered microbial systems can convert carbon-rich industrial waste into high-value products.
• University of NottinghamsecondaryStrategic or Co-development PartnerUniversity of Nottingham is a spoke partner in the Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop), alongside UCL and Imperial College London.
• Imperial College LondonsecondaryStrategic or Co-development PartnerImperial College London is a spoke partner in the Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop).
• University of WarwicksecondaryStrategic or Co-development PartnerUniversity of Warwick is a partner in the Sustainable Engineering Plastics (SEP) Hub (£13.6m) alongside MIB and UCL, working on assessing and improving sustainability of greener materials and remanufacturing processes.
• Diamond Light SourcesecondaryStrategic or Co-development PartnerColin Levy, Head of X-ray diffraction at MIB, is an elected member of the Diamond User Committee, providing feedback and user perspective on operations and proposed upgrades to the UK's national synchrotron facility used for macromolecular crystallography and serial crystallographic studies.
• University of LeicestersecondaryStrategic or Co-development PartnerDr Fraser Macrae from the University of Leeds co-led the 'blood on demand' cryopreservation research alongside Professor Matthew Gibson from MIB, demonstrating cross-institutional collaboration in therapeutic biotechnology development.
• CADDA (Centre for Advanced Diagnostic Development and Application)secondaryStrategic or Co-development PartnerCADDA brings together leading academic, clinical and industry expertise as a national programme accelerating the development and translation of innovative diagnostics. It connects researchers, SMEs and healthcare providers across human and animal health.
• COEBP (Centre of Excellence in Biopharmaceuticals)coreStrategic or Co-development PartnerCOEBP brings together expertise in discovery and protein expression, bioprocessing and chemical engineering, and formulation and delivery, mirroring the commercial pipeline for biological therapeutics and advanced therapy medicinal products (ATMPs). Works closely with key players in the biomanufacturing industry.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Others

• Manchester BIOGEL / Cell Guidance Systems: An MIB-originated spin-out (acquired by Cell Guidance Systems in 2023) commercialising PeptiGel hydrogels. Included because it represents a successful translation pathway from MIB research, illustrating how the consortium's outputs reach market — though now operating as part of a larger acquirer.
• SynBioBeta: Global synthetic biology industry network and conference organiser. Comparable as a community-led GTM vehicle for engineering biology ecosystem building — SynBioBeta operates at global scale where IBIC is regionally focused, making it an adjacent rather than directly competing platform.
• Wellcome Sanger Institute: UK genomics research institute with deep ties to biotech translation. While its core focus is genomics rather than industrial biotechnology, it is a comparable large UK life sciences research institute with industry collaboration and translational programmes that overlap with MIB's broader biotech ecosystem.

Regional players

• Rosalind Franklin Institute: UK national life sciences research institute focused on new technologies for biological imaging, diagnostics and therapeutics. Comparable as a UK research organisation driving translational biotech, though with a different technical focus (imaging/instrumentation rather than industrial biotech).
• BioMADE: US Bioindustrial Manufacturing Innovation Institute, established with Department of Defense funding to accelerate bioindustrial manufacturing. Operates as a comparable public-private consortium model in the US, but focused on defence and US-domestic industrial base rather than IB translation.
• VTT Technical Research Centre of Finland: VTT is a Finnish government-owned research institution with deep industrial biotechnology and synthetic biology capabilities, including pilot-scale bioprocessing facilities. Operates a similar multi-disciplinary biotech research model to MIB but serves a different national ecosystem and offers broader applied research scope.
• Fraunhofer IGB: Germany's Fraunhofer Institute for Interfacial Engineering and Biotechnology conducts applied research across industrial biotechnology, bioprocess engineering and bioeconomy. Comparable in role as a national applied biotech research hub but operating as part of the larger Fraunhofer network with much broader scale.

Broad incumbents

• Centre for Process Innovation (CPI): CPI is a UK technology and innovation centre operating across multiple sectors including biologics and industrial biotechnology. As part of the High Value Manufacturing Catapult, it offers process development and scale-up facilities comparable to MIB's BioAutomation and bioprocess capabilities, but across a broader portfolio.

Direct peers

• Industrial Biotechnology Innovation Centre (IBioIC): Scotland's Industrial Biotechnology Innovation Centre is the closest direct UK counterpart to IBIC — both are publicly-funded innovation centres dedicated to accelerating industrial biotechnology translation by connecting academia, industry and government. IBioIC runs the Collaborative Training Partnership that even funds PhDs at MIB.
• John Innes Centre: UK research centre focused on plant science and microbiology, and a named partner in MIB's synPAC project. Comparable as a UK BBSRC-funded research institution with strong industrial biotechnology, synthetic biology and bioeconomy activities that overlap with MIB's core capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/uommib.bsky.social
• LinkedInlinkedin.com/company/industrial-biotechnology-innovation-catalyst

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Industrial Biotechnology Innovation Catalyst